New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for TNBC

With pembrolizumab plus chemotherapy now approved for PD-L1–positive advanced TNBC, how can we leverage this regimen for treating patients with this challenging disease? Here’s my take.

Heather McArthur, MD, MPH Released: November 20, 2020

With sacituzumab govitecan, pembrolizumab, and atezolizumab all now approved for advanced TNBC, how do we sequence these agents and how does a BRCA1/2 mutation affect sequencing decisions? Here are my thoughts.

Kevin Kalinsky, MD, MS Released: December 23, 2020